Clik here to view.
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy...
IRVINE, Calif. CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced today it has triggered the first...
View ArticleClik here to view.
ITM and ANSTO Announce Extension of Licensing Agreement for the Production...
MUNICH & SYDNEY ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and the Australian Nuclear Science and Technology Organisation (ANSTO), a public research...
View ArticleClik here to view.
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for...
EMERYVILLE, Calif. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616) has received approval from China’s National Medical...
View ArticleClik here to view.
Curia Unveils Comprehensive mRNA Solution
ALBANY, N.Y. Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process...
View ArticleClik here to view.
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in...
TOKYO, MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
View ArticleClik here to view.
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial...
View ArticleClik here to view.
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1...
BROOKLYN, N.Y. Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Accutar Biotechnology、前立腺がんを対象としたAC0176の第1相臨床試験のIND申請をFDAが承認したと発表
米ニューヨーク州ブルックリン （ビジネスワイヤ） — 人工知能（AI）の力を活用した創薬に傾注するバイオテクノロジー企業のAccutar Biotechnology,...
View ArticleClik here to view.
ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted...
MUNICH & GARCHING, Germany & HONG KONG ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Grand Pharmaceutical Group Limited (GP) a diversified...
View ArticleClik here to view.
Accutar Biotechnology宣布FDA批准AC0176用于治疗前列腺癌的1期试验的IND申请
纽约布鲁克林 (美国商业资讯)–专注于利用人工智能(AI)赋能药物发现的生物技术公司Accutar Biotechnology, Inc.今天宣布，美国食品药品管理局(FDA)已批准该公司在研新药AC0176用于治疗转移性去势难治性前列腺癌(mCRPC)患者的试验用新药申请(IND)。AC0176是一种口服生物可利用(orally...
View ArticleClik here to view.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for...
KENILWORTH, N.J. & TOKYO Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has...
View ArticleClik here to view.
Valemetostat New Drug Application Submitted in Japan for Treatment of...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
Babson Graduate Pooja Ika Launches eternalHealth, the First New Medicare...
BOSTON eternalHealth, the first new health plan to be approved in Massachusetts since 2013, has officially announced its launch of the company, delivering high-quality and affordable Medicare...
View ArticleClik here to view.
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in...
TOKYO, MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
View ArticleClik here to view.
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial...
View ArticleClik here to view.
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune...
YONGIN, South Korea & MUMBAI, India GC Cell (KOSDAQ:144510) and Rivaara Immune Private Limited today announced that they have entered into an exclusive licensing agreement, pursuant to which...
View ArticleClik here to view.
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P....
View ArticleClik here to view.
イクスーダ・セラピューティクス、レゴケム・バイオサイエンシズからのHer2抗体薬物複合体プログラムのライセンス契約により、臨床パイプラインを強化
英ニューカッスル （ビジネスワイヤ） — 治療指数を高めた新世代の抗体薬物複合体（ADC）の開発を手掛けるイクスーダ・セラピューティクス（イクスーダ）は本日、専有的な創薬技術を活用した次世代の新規治療薬の開発に傾注する韓国のバイオ製薬企業レゴケム・バイオサイエンシズ（LCB）とライセンス／商業化契約を結び、当社の差別化ADCパイプラインをさらに拡大すると発表しました。...
View Article